10.2 Having considered the above options the Working Group concluded that there are essentially only two available options: Option 1 to bring GBL and 1,4-BD under control of the Misuse of Drugs Act, 1971, with or without a combination of Option 4 to include GBL and 1,4-BD in a licensing system;or Option 5 watch and wait.
10.3 After consideration of the evidence presented in this report and the options outlined above, the ACMD recommends that GBL and 1,4-BD are brought under control of the Misuse of Drugs Act 1971 and licensing arrangements are made for their legitimate industrial use. The harms and misuse of GBL and 1,4-BD are considered commensurate with Class C of the Misuse of Drugs Act 1971; classified in Schedule 1 of the Misuse of Drugs Regulations (having no recognised medicinal use). However, the ACMD is mindful of the potential impact of control upon the legitimate use of GBL and 1,4-BD and therefore also recommends that the Government consults specifically on this aspect, and that the ACMD comments further following the outcome of the consultation before finalising its recommendation